© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
A panel of expert oncologists review three clinical cases to highlight key clinical trial data and optimal approaches to treating patients with HER2+ breast cancer.
May 25th 2022
Centering discussion on a patient case of early-stage HER2+ breast cancer, expert oncologists consider when it is appropriate to utilize neoadjuvant therapy.
Comprehensive insight on the neoadjuvant treatment armamentarium for early-stage HER2+ breast cancer and the appropriate selection of specific agents.
June 1st 2022
Shifting their focus to the adjuvant setting, expert panelists review the optimal selection of therapy following surgery in early-stage HER2+ breast cancer.
A focused discussion on the subcutaneous formulation of trastuzumab and pertuzumab in patients with early-stage HER2+ breast cancer.
June 8th 2022
Panelists provide a broad overview of treatment options available for patients diagnosed with HER2+ metastatic breast cancer.
Shared insight on the DESTINY-Breast03 trial, which analyzed trastuzumab deruxtecan therapy in patients with HER2+ metastatic breast cancer.
June 15th 2022
Comprehensive discussion on the presence and management of interstitial lung disease in patients being treated for HER2+ metastatic breast cancer.
Expert oncologists share brief notes on their real-world experience managing HER2+ metastatic breast cancer with trastuzumab deruxtecan.
June 22nd 2022
Centering discussion on a patient case of HER2+ breast cancer with brain metastases, experts consider optimal treatment regimens in this setting.
Focusing on the HER2CLIMB regimen, experts consider appropriate treatment options for patients with HER2+ metastatic breast cancer in the third-line setting and beyond.